Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology

Parag A. Majmudar, Steven C. Schallhorn, John B. Cason, Kendall E. Donaldson, George D. Kymionis, Roni M. Shtein, Steven Verity, Ayad A. Farjo

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Objective To review the published literature assessing the efficacy and safety of mitomycin-C (MMC) as an adjunctive treatment in corneal surface excimer laser ablation procedures. Methods Literature searches of the PubMed and Cochrane Library databases were last conducted on August 19, 2014, without language or date limitations. The searches retrieved a total of 239 references. Of these, members of the Ophthalmic Technology Assessment Committee Refractive Management/Intervention Panel selected 26 articles that were considered to be of high or medium clinical relevance, and the panel methodologist rated each article according to the strength of evidence. Ten studies were rated as level I evidence, 5 studies were rated as level II evidence, and the remaining 11 studies were rated as level III evidence. Results The majority of the articles surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation procedures. When MMC is applied in the appropriate concentration and confined to the central cornea, the incidence of post-surface ablation haze is decreased. Although a minority of studies that evaluated endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcomes were reported. Conclusions Over the past 15 years, the use of MMC during surgery in surface ablation has become widespread. There is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against haze in higher myopic ablations. Although there are reports of decreased endothelial counts after the administration of MMC during surgery, the clinical significance of this finding remains uncertain, because no adverse outcomes were reported with as much as 5 years of follow-up. Optimal dosage, effectiveness as prophylaxis in lower myopic and hyperopic ablations, and long-term safety, particularly in eyes with reduced corneal endothelial cell counts from prior intraocular surgery, have yet to be established.

Original languageEnglish (US)
Pages (from-to)1085-1095
Number of pages11
JournalOphthalmology
Volume122
Issue number6
DOIs
StatePublished - Jun 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Majmudar, P. A., Schallhorn, S. C., Cason, J. B., Donaldson, K. E., Kymionis, G. D., Shtein, R. M., Verity, S., & Farjo, A. A. (2015). Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology. Ophthalmology, 122(6), 1085-1095. https://doi.org/10.1016/j.ophtha.2015.01.019